A new COVID variant, NB.1.8.1, linked to a surge in China, has been detected in the United States via international travelers ...

A new Covid variant, NB.1.8.1, is detected in US airports. The variant is driving a surge in cases across China. Cases are ...

Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

A new COVID-19 variant, NB.1.8.1, linked to a surge in cases across China and parts of Asia, has now been detected in the ...

The U.S. has detected the NB.1.8.1 COVID-19 variant, dominant in China, through airport screenings and health departments ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...